The FDA has approved Gilead Sciences Inc’s antiviral drug remdesivir for treating patients hospitalized with COVID-19, making it the first and only drug approved for the disease in the United States.
The COVID-19 pandemic dramatically impacted outpatient care - numbers, scope, quality, etc, but a recent study suggests that while COVID has changed the scope of care, the numbers of outpatient visits have risen to near pre-pandemic numbers.
The NEJM reports on a controlled clinical trial showing patients hospitalized with Covid-19 given hydroxychloroquine (HCQ) do not have a lower incidence of death compared to those receiving routine care.
Dr. Jack Cush Reviews the news and journal articles from the past week on RheumNow.com.
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.
Numerous previous studies have questioned the efficacy or protection afforded by hydroxychloroquine (HCQ) for COVID-19 and studies have show that HCQ has failed when given as post-exposure prophylaxis to health care workers (HCWs). A new randomized controlled trial has shown that HCQ failed when
JAMA Dermatology expands the spectrum of complications seen with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection describing cutaneous purpura and livedo lesions in patients with severe COVID-19.